BioSpace News Archive

nanoMesh™ LLC, a subsidiary of Exogenesis Corporation, announced today that it has successfully initiated First-In-Man implantation of its proprietary soft tissue repair device, Exogenesis nanoMesh™

IRRAS, a commercial-stage medical technology company with a comprehensive portfolio of innovative products for neurocritical care, announced that its Board of Directors has appointed Will Martin as President and Chief Executive Officer of the Company.

PRA offers post-authorization safety solutions to keep up with the speed of COVID-19 vaccine and therapeutic pharmacovigilance requirements

CareDx, Inc. (Nasdaq: CDNA), a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers, today announced it will report financial results for the first quarter 2021 after market close on Wednesday, May 5, 2021.

NeuBase Therapeutics, Inc. (Nasdaq: NBSE) (“NeuBase”), a biotechnology company accelerating the genetic revolution with a new class of precision genetic medicines, announced today that it has commenced an underwritten public offering of shares of common stock.

Ascendis Pharma A/S (Nasdaq: ASND), a biopharmaceutical company that utilizes its innovative TransCon technologies to address unmet medical needs, today announced presentations featuring TransCon hGH (lonapegsomatropin) at two upcoming medical conferences: Pediatric Endocrinology Nursing Society (PENS) national conference, taking place virtually April 21-23,

SAB Biotherapeutics (SAB), a clinical-stage biopharmaceutical company developing a novel immunotherapy platform to produce specifically targeted, high potency, fully-human polyclonal antibodies, today announced that the first patient has been dosed in its Phase 2/3 study evaluating the safety and efficacy of SAB-185, a polyclonal antibody therapeutic candidate in non-hospitalized adults with mild to moderate COVID-19 as part of the NIH’s ACTIV-2 master protocol.

Healthcare Solutions Management Group, Inc., a Delaware corporation and successor in interest to Verity Delaware Inc., a Delaware corporation, entered into a Merger Agreement by and between the Company, Verity Merger Corp., and Healthcare Solutions Holdings, Inc.

Renowned expert in myeloproliferative neoplasms research joins to guide development efforts and accelerate progress for patient community

The 221b Foundation, a nonprofit organization established by Sherlock Biosciences to address the global COVID-19 pandemic while promoting diverse representation in STEM, today announced that it has granted Cooper International and United PPE licenses to develop and manufacture COVID-19 diagnostic tests using Sherlock’s CRISPR technology.